Coumarinyl pyrazole derivatives of INH: Promising antimycobacterial agents

Medicinal Chemistry Research

Volumn 22, Issue 5, 2013, Pages 2279-2283

  Aragade, Prashant ^a   Palkar, Mahesh ^a   Ronad, Pradeepkumar ^a   Satyanarayana, Darbhamulla ^b  

^a KLES's College of Pharmacy   (India)

^b NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

Antimycobacterial activity; Coumarin; Isonicotinic acid hydrazide; Mycobacterium tuberculosis; Pyrazole

Indexed keywords

ANTIMYCOBACTERIAL AGENT; COUMARINYL PYRAZOLE DERIVATIVE; ISONIAZID DERIVATIVE; PYRAZOLE DERIVATIVE; RESAZURIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOPHORE;

EID: 84879688743     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0222-8     Document Type: Article

References (25)

1. Ali MA, Shaharyar M, Siddiqui AA (2007) Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives. Eur J Med Chem 42:268-275
2. Aragade P, Maddi V, Khode S, Palkar M, Ronad P, Mamledesai S, Satyanarayana D (2009) Synthesis and antibacterial activity of new series of 3-[3-(substituted phenyl)-1-isonicotinoyl-1H-pyrazol-5-yl]-2H-chromen-2-one derivatives. Arch Pharm Chem Life Sci 342:361-366
3. Bolakatti G, Maddi V, Mamledesai SN, Ronad PM, Palkar MB, Swamy S (2008) Synthesis and evaluation of anti-inflammatory and analgesic activities of novel series of coumarin mannich bases. Arzneim Forsch 58:515-520
4. Collins FM (1989) Mycobacterial disease, immunosuppression and acquired immunodeficiency syndrome. Clin Microbiol Rev 2:360-377
5. Collins LA, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against M. tuberculosis and M. ovium. Antimicrob Agents Chemother 41:1004-1009
6. Dessen AA, Quemard JS, Blanchard WR, Sacchettini JC (1995) Crystal structure and function of the isoniazid target of M. tuberculosis. Science 267:1638-1641
7. Genin MJ, Allwine DA, Anderson DJ, Barbachyn MR, Emmert DE et al (2000) Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl) oxazolidinones with expanded activity against the fastidious gram-negative organisms H. influenzae and M. catarrhalis. J Med Chem 43:953-970
8. Graham NM, Galai KE, Nelson J, Bonds AM, Rizzo RT (1996) Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 156:889-894
9. Halsey NA, Coberly JS, Desormeaux J, Losikoff P (1998) Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351:786-792
10. Inderlied CB, Kemper CA, Bermudez LE (1993) The Mycobacterium avium complex. Clin Microbiol Rev 6:266-310
11. Karthikeyan MS, Holla BS, Kumari NS (2007) Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines. Eur J Med Chem 42:30-36
12. Khode S, Maddi V, Aragade P, Palkar M, Ronad P, Mamledesai S, Thippeswamy AHM, Satyanarayana D (2009) Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents. Eur J Med Chem 44:1682-1688
13. Knoevenagel E (1898) Condensationn zwischen malonester und aldehyden unter dem einfluss von ammoniak und organischen aminen. Chem Ber 31:2596
14. Kopec AE, Zwolska Z (2002) Bioavailability factors of INH in fast and slow acetylators, healthy volunteers. Acta Poloniae Pharm 59:452-457
15. Kucukguzel SG, Rollas S (2000) Synthesis, characterization and pharmacological properties of some 4-arylhydrazono-2-pyrazoline-5-one derivatives obtained from heterocyclic amines. Eur J Med Chem 35:761-765
16. Kucukguzel SG, Rollas S (2002) Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. IL Farmaco 57:583-587
17. Mandell GL, Petri WA (1996) Antimicrobial agents used in the chemotherapy of tuberculosis. In: Hardman J et al (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 1155-1174
18. Morris S, Bai GH, Suffys P, Portilo-Gomez L, Fairchok M, Rouse D (1995) Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 171:954-960
19. Nauduri D, Reddy GB (1998) Antibacterials and antimycotics. Part 1. Synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull 46:1254-1257
20. Reis RS, Neves I, Lourenco SLS, Fonseca LS, Lourenco MCS (2004) Comparison of flow cytometric and alamar blue tests with the proportional method for testing susceptibility of M. tuberculosis to rifampin and isoniazid. J Clin Microbiol 42:2247-2248
21. Sensi P, Grassi G (1996) Antimycobacterial agents. In: Wolff ME (ed) Burger's medicinal chemistry and drug discovery, 5th edn. Wiley, New York, pp 575-635
22. Shaharyar M, Siddiqui AA, Ali MA, Sriram D, Yogeeswari P (2006a) Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(4′- hydroxy-3′-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 16:3947-3952
23. Shaharyar M, Siddiqui AA, Ali MA (2006b) Synthesis and evaluation of phenoxy acetic acid derivatives as anti-mycobacterial agent. Bioorg Med Chem Lett 16:4571-4578
24. Shenoy GG, Bhat AR, Bhat GV, Kotian M (2001) Synthesis of pyrazoles and isoxazole in triethanolamine medium Ind. J Heterocycl Chem 10:197-199
25. Telzak EE, Sepkowitz K, Alpert P (1995) Multidrug resistant tuberculosis in patients without HIV infection. N Engl J Med 333:907-911